Novartis (NVS) closed the latest trading day at $99.77, indicating a -1.58% change from the previous session's end. This move lagged the S&P 500's daily gain of 1.12%. Elsewhere, the Dow gained 0.61%, while the tech-heavy Nasdaq added 1.54%.Coming into today, shares of the drugmaker had gained 0.84% in the past month. In that same time, the Medical sector gained 2.49%, while the S&P 500 gained 2.06%.Investors will be eagerly watching for the performance of Novartis in its upcoming earnings disclosure. On th ...

In the latest trading session, Novartis (NVS) closed at $101.37, marking a +0.66% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.11%. Meanwhile, the Dow gained 0.12%, and the Nasdaq, a tech-heavy index, lost 0.41%.Prior to today's trading, shares of the drugmaker had lost 0.32% over the past month. This has lagged the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7% in that time.The investment community will be closely monitoring the performance of No ...

Novartis (NVS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned -4.1% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Novartis belongs, has gained 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumo ...

Novartis (NVS) ended the recent trading session at $102.22, demonstrating a -0.9% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.06%, and the technology-dominated Nasdaq saw a decrease of 0.55%.Coming into today, shares of the drugmaker had lost 4.27% in the past month. In that same time, the Medical sector gained 5.93%, while the S&P 500 gained 3.98%.Analysts and investors alike will be keeping a c ...

Novartis (NVS) announced that it will acquire Germany-based global biopharmaceutical company MorphoSys AG (MOR) to expand its oncology portfolio.Financial Terms of the AcquisitionNovartis will make a voluntary public takeover offer for all no-par value bearer shares of MorphoSys AG for €68 per share or an aggregate of €2.7 billion. The acquisition is expected to close in the first half of 2024.The transaction is contingent on customary closing conditions. This includes acceptance of the takeover offer by at ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Key TakeawaysNovartis missed forecasts for quarterly results and guidance, and ended a cancer drug study.The drug maker's sales increased, boosted by its heart medicine, Entresto.Novartis stopped research on an experimental cancer treatment, sabatolimab, after it failed to meet its primary endpoint in a Phase 3 trial.Novartis shares, which hit an all-time high earlier this month, were down more than 3% in mid-afternoon trading.Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell ...

Novartis AG (NYSE:NVS) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Andrew Baum - Citi Florent Cespedes - Societe Generale Graham Parry - Bank of America John Priestner - JPMorgan Tim Anderson - Wolfe Research Simon Baker - Redburn Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities ...

Swiss pharma giant Novartis AG (NVS) reported lower-than-expected results in the fourth quarter of 2023. Core earnings (excluding one-time charges) of $1.53 per share missed the Zacks Consensus Estimate of $1.64. Higher expenses pulled down the bottom line. The figure was, nevertheless, up from $1.39 recorded a year ago.Revenues of $11.4 billion climbed 8% from the year-ago quarter's level. On a constant currency basis, sales increased 10%, driven by momentum in Entresto, Kesimpta, Kisqali, Cosentyx and Plu ...

For the quarter ended December 2023, Novartis (NVS) reported revenue of $11.42 billion, down 10% over the same period last year. EPS came in at $1.53, compared to $1.51 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $11.69 billion, representing a surprise of -2.29%. The company delivered an EPS surprise of -6.71%, with the consensus EPS estimate being $1.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street e ...